Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
This article was originally published in PharmAsia News
Executive Summary
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets